Johnson & Johnson's Q4 2015 earnings call highlighted strong underlying operational growth despite currency headwinds and reduced sales from divestitures. The company exceeded earnings estimates, provided optimistic guidance for 2016, and announced strategic restructuring in its Medical Devices segment to drive future growth. Management's confident tone and commitment to innovation suggest positive short-term momentum for the stock.

[1]